Sign Up for a Free Account


Artificial intelligence could analyze speech to help diagnose Alzheimer disease

Alzheimer disease is notoriously difficult to diagnose. Typically, doctors use a combination of cognitive tests, brain imaging, and observation of behavior that can be expensive and time-consuming. But what if a quick voice sample, easily taken at a person’s home, could help identify a patient with Alzheimer disease?

A company called Canary Speech is creating technology that uses algorithms to analyze short voice samples for signs of Alzheimer disease and other conditions. Deep learning provider Syntiant recently announced a collaboration with Canary Speech, which will allow Canary to take a technology that is mostly used in doctor’s offices and hospitals into a person’s home via a medical device. Although some research has found deep-learning techniques using voice and other types of data to be highly accurate in classifying those with Alzheimer disease and other conditions in a lab setting, it’s possible the results would be different in the real world. Nevertheless, artificial intelligence and deep-learning techniques could become helpful tools in making a difficult diagnosis.

Most people think of Alzheimer disease , the most common form of dementia, as affecting memory. But research suggests that Alzheimer disease can impact speech and language even in the disease’s earliest stages, before most symptoms are noticeable. Although people can’t usually pick up on these subtle effects, a deep-learning model, trained on the voices of tens of thousands of people with and without these conditions, may be able to distinguish these differences.

“What you’re interested in is, what is the central nervous system telling you that is being conveyed through the creation of speech?” says Henry O’Connell, CEO and cofounder of Canary Speech. “That's what Canary Speech does—we analyze that data set.”

Until now, O’Connell says that the algorithm has been cloud-based, but Canary’s collaboration with Syntiant allows for a chip-based application, which is faster and has more memory and storage capacity. The new technology is meant to be incorporated into a wearable device and take less than a second to analyze a 20- or 30-second sample of speech for conditions like Alzheimer disease as well as anxiety, depression, and even general energy level. O’Connell says that Canary’s system is about 92.5% accurate when it comes to correctly distinguishing between the voices of people with and without Alzheimer disease. There is some research to suggest that conditions like depression and anxiety impact speech, and O’Connell says that Canary is working to test and improve the accuracy of algorithms to detect these conditions.

Other voice-based technologies have had similar success, says Frank Rudzicz, an associate professor of computer science at the University of Toronto and cofounder of Winterlight Labs, which makes a similar product to Canary Speech. In a 2016 study, Rudzicz and other researchers used simple machine learning methods to analyze the speech of people with and without Alzheimer disease with an accuracy of about 81%.

“With deep learning, you would just give the raw data to these deep neural networks, and then the deep neural networks automatically produce their own internal representations,” Rudzicz says. Like all deep-learning algorithms, this creates a “black box”—meaning it’s impossible to know exactly what aspects of speech the algorithm is homing in on. With deep learning, he says, the accuracy of these algorithms has risen above 90%.

Previously, programmers have used deep learning alongside medical imaging of the brain, such as MRI scans. In studies, many of these methods are similarly accurate—usually above 90% accuracy. In a December 2021 study, programmers successfully trained an algorithm to not only distinguish between the brains of cognitively normal people and those with Alzheimer disease but also between those with mild cognitive impairment, in many cases an early precursor to Alzheimer disease, whose brains were either more similar to those of healthy people or more similar to those with Alzheimer disease. Distinguishing these subtypes is especially important because not everyone with mild cognitive impairment goes on to develop Alzheimer disease.

“We want to have methods to stratify individuals along the Alzheimer disease continuum,” says Eran Dayan, an assistant professor of radiology at the University of North Carolina, Chapel Hill and an author of the 2021 study. “These are subjects who are likely to progress to Alzheimer disease.”

Identifying these patients as early as possible, Dayan says, will likely be crucial in effectively treating their diseases. He also says that, generally, scan-based deep learning has a similarly high efficacy rate, at least in classification studies done in the lab. Whether these technologies will be just as effective in the real world is less clear, he says, though they are still likely to work well. He says more research is needed to know for sure.

Another reason for concern, Dayan says, is potential biases, which recent research has shown that artificial intelligence can harbor if there is not enough variety in the data the algorithm is trained on. For instance, Rudzicz says it’s possible that an algorithm trained using speech samples from people in Toronto would not work as well in a rural area. O’Connell says that the algorithm that Canary Speech uses analyzes nonlanguage elements of speech and that they have versions of the technologies used in other countries, like Japan and China, that are trained using data from native language speakers.

“We validate our model and train it in that system, in that environment, for performance,” he says.

Though Canary’s collaboration with Syntiant may make remote, real-time monitoring possible, O’Connell personally believes a formal diagnosis should come from a doctor, with this technology serving as another tool in making the diagnosis. Dayan agrees. “Artificial intelligence, in the coming years, I hope will help assist doctors, but absolutely not replace them,” he says.

Source: News Release
IEEE Spectrum

January 24, 2022

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125